INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID‐19 (INHALE‐HEP): Protocol and statistical analysis plan for an investigator‐initiated international metatrial of randomised studies

Autor: Alicia Vilaseca, Mary P. Carroll, Antonio Artigas, Rabab S. Mahrous, Marta Camprubí-Rimblas, Hwan-Jin Yoon, Christopher Hillman, Lex van Loon, Janis K. Shute, Barry Dixon, Miles W. Carroll, Gilberto De Nucci, Tarek I. Ismail, Mohamed Badr, Dave Singh, Frank van Haren, John G. Laffey, Anusha Belani, Carlos Eduardo Sverdloff, Clive P. Page, Tom Wilkinson, Sabrina Staas, Khine Sann, Thomas Smoot, David W. Cosgrave, Caitlin Sas, Alice Richardson, Ruben Barbera, Roger J Smith

Publikováno v: British Journal of Clinical Pharmacology
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP

Aims: inhaled nebulised unfractionated heparin (UFH) has a strong scientific and biological rationale that warrants urgent investigation of its therapeutic potential in patients with COVID‐19. UFH has antiviral effects and prevents the SARS‐CoV�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a464917b105c48466aae2addb3270425
https://eprints.soton.ac.uk/446588/